Your browser is no longer supported. Please, upgrade your browser.
MannKind Corporation
Index- P/E- EPS (ttm)-0.21 Insider Own0.90% Shs Outstand229.67M Perf Week4.73%
Market Cap898.06M Forward P/E- EPS next Y-0.11 Insider Trans2.25% Shs Float224.21M Perf Month-4.84%
Income-45.10M PEG- EPS next Q-0.04 Inst Own30.00% Short Float8.57% Perf Quarter75.25%
Sales62.70M P/S14.32 EPS this Y56.00% Inst Trans-0.20% Short Ratio4.74 Perf Half Y114.55%
Book/sh-0.81 P/B- EPS next Y38.90% ROA-48.40% Target Price3.30 Perf Year108.24%
Cash/sh0.21 P/C17.14 EPS next 5Y35.60% ROE23.90% 52W Range0.80 - 4.21 Perf YTD13.10%
Dividend- P/FCF- EPS past 5Y36.50% ROI57.40% 52W High-15.91% Beta2.16
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin60.30% 52W Low342.50% ATR0.26
Employees233 Current Ratio0.60 Sales Q/Q5.50% Oper. Margin-56.60% RSI (14)57.08 Volatility6.70% 7.44%
OptionableYes Debt/Eq- EPS Q/Q5.50% Profit Margin-71.90% Rel Volume0.80 Prev Close3.41
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume4.05M Price3.54
Recom1.40 SMA206.74% SMA5012.69% SMA20074.56% Volume3,223,429 Change3.81%
Dec-24-19Initiated Oppenheimer Outperform $2.50
Oct-25-19Initiated Cantor Fitzgerald Overweight $3
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Jan-04-21 05:00PM  
Dec-29-20 08:53AM  
Dec-18-20 07:45AM  
Dec-17-20 04:44PM  
Dec-10-20 08:00AM  
Dec-07-20 11:33PM  
Dec-01-20 08:00AM  
Nov-30-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 05:00PM  
Nov-10-20 10:15AM  
Nov-08-20 09:37AM  
Nov-06-20 08:44PM  
Nov-04-20 05:15PM  
Oct-29-20 08:00AM  
Oct-28-20 12:32PM  
Oct-23-20 10:38AM  
Sep-08-20 08:00AM  
Aug-31-20 09:00AM  
Aug-24-20 02:28PM  
Aug-20-20 08:39AM  
Aug-07-20 05:00PM  
Aug-05-20 06:35PM  
Jul-29-20 05:00PM  
Jul-20-20 09:00AM  
Jun-22-20 08:30AM  
Jun-18-20 08:49AM  
Jun-17-20 05:00PM  
Jun-15-20 04:07PM  
Jun-13-20 12:00PM  
Jun-05-20 01:10PM  
May-25-20 11:12AM  
May-19-20 08:44PM  
May-07-20 04:36AM  
May-06-20 05:15PM  
Apr-29-20 05:00PM  
Apr-28-20 12:33PM  
Apr-15-20 08:00AM  
Mar-31-20 10:54AM  
Mar-24-20 09:00AM  
Mar-17-20 09:00AM  
Mar-07-20 03:31AM  
Feb-25-20 08:00AM  
Feb-24-20 06:25PM  
Feb-20-20 09:00AM  
Feb-18-20 09:00AM  
Jan-22-20 09:22AM  
Jan-20-20 04:37AM  
Jan-10-20 05:00AM  
Jan-06-20 08:00AM  
Dec-20-19 06:21PM  
Nov-29-19 09:00AM  
Nov-21-19 09:00AM  
Nov-16-19 09:39PM  
Nov-12-19 02:26PM  
Nov-06-19 08:00AM  
Nov-04-19 09:00AM  
Oct-30-19 09:00AM  
Sep-26-19 09:00AM  
Sep-19-19 09:00AM  
Sep-12-19 11:25AM  
Sep-10-19 03:30PM  
Aug-30-19 09:00AM  
Aug-23-19 12:00PM  
Aug-16-19 08:35AM  
Aug-08-19 11:23AM  
Aug-07-19 04:01PM  
Aug-05-19 09:00AM  
Aug-01-19 05:02PM  
Jul-31-19 09:00AM  
Jul-18-19 08:52AM  
Jul-15-19 09:00AM  
Jul-11-19 04:14PM  
Jul-09-19 12:09PM  
Jun-14-19 10:00AM  
Jun-12-19 09:00AM  
Jun-09-19 02:00PM  
Jun-03-19 08:00AM  
May-18-19 08:03AM  
May-17-19 08:03AM  
May-16-19 04:01PM  
May-14-19 03:47PM  
May-08-19 09:24AM  
May-07-19 05:53PM  
May-02-19 09:26AM  
Apr-30-19 09:00AM  
Apr-25-19 09:45AM  
Apr-02-19 06:00AM  
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder Steven B.Chief Financial OfficerJul 31Buy1.251,5221,90333,265Aug 04 06:45 PM
Tross Stuart AChief People & Workpl OfficerJul 31Buy1.255,0006,250114,720Aug 04 06:41 PM
Kendall David MChief Medical OfficerJul 31Buy1.254,0415,05141,059Aug 04 06:39 PM
Castagna MichaelChief Executive OfficerJul 31Buy1.255,0006,250203,560Aug 04 06:38 PM
Castagna MichaelChief Executive OfficerJun 15Buy1.4110,36314,63810,000Jun 16 05:36 PM
Castagna MichaelChief Executive OfficerJun 15Buy1.4930,00044,700198,560Jun 16 05:36 PM
Castagna MichaelChief Executive OfficerJun 12Buy1.41689668Jun 16 05:36 PM
Tross Stuart AChief People & Workpl OfficerJan 31Buy0.955,0004,750124,741Feb 03 09:17 PM
McCauley PatrickChief Commercial OfficerJan 31Buy0.955,0004,750100,433Feb 03 09:16 PM
Kendall David MChief Medical OfficerJan 31Buy0.952,3042,18952,154Feb 03 09:15 PM
Castagna MichaelChief Executive OfficerJan 31Buy0.955,0004,750168,560Feb 03 09:14 PM
Binder Steven B.Chief Financial OfficerJan 31Buy0.952,1682,06048,204Feb 03 09:14 PM